Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Basic characteristics of the study participants Variables | Total (n = 6732) | GDM | Statistics | P | Yes (n = 253) | No (n = 6479): 25OHD2 + 25OHD3, nmol/L, Mean (S.E) | 90.85 (1.75) | 83.71 (4.16) | 91.14 (1.74) | t = − 1.99 | 0.051

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) between 2007 and 2010, between 2013 and 2014, and between 2017 and 2018 were retrospectively included in this cross-sectional study.

Source: Abstract.

Women were identified as developing DM if they reported having a diagnosis of DM (other than during pregnancy) or, or if they had a haemoglobin (A1C) level was ≥ 6.5%, a fasting plasma glucose level ≥ 126 mg/dL, or 2-h plasma glucose level ≥ 200 mg/dL if they had not previously been diagnosed with DM [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Association of a history of gestational diabetes mellitus with osteoporosis, bone mineral density, and trabecular bone score in postmenopausal women

Cross-sectional study · Diabetology & Metabolic Syndrome · 2023

Original publication title

Association of a history of gestational diabetes mellitus with osteoporosis, bone mineral density, and trabecular bone score in postmenopausal women

Boqi Lu; Liping Zhang

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

A history of GDM was associated with a higher risk of osteoporosis in postmenopausal women, and there was an association between a history of GDM and osteoporosis in postmenopausal women with an obese BMI.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Osteoporosis is a musculoskeletal disease characterized by loss of bone mass and bone microstructure damage [1]. Postmenopausal women experience a steady loss of bone mass due to aging and hormonal changes, leading to osteoporosis [2]. More than 10 million Americans over the age of 50 years suffer from osteoporosis, and this number is expected to increase in the future with the expected growth of the elderly population [3]. Each year, osteoporosis results in more than 9 million fractures worldwide [4].

Osteoporotic fractures in postmenopausal women are associated with poor quality of life and reduced life expectancy [5]. The gold standard for diagnosing osteoporosis is the measurement of bone mineral density (BMD) using a dual-energy X-ray absorptiometry (DEXA) scan. Given the damage caused by osteoporosis and the fact that BMD is a significant marker of bone mass, it is necessary to identify factors associated with BMD and osteoporosis.

Diabetes mellitus (DM) has been recognized as one of the risk factors for osteoporotic fractures [6]. Gestational DM (GDM), a common complication of pregnancy, is defined as glucose intolerance that first diagnosed during pregnancy [7]. BMD in women with GDM was reported to be lower than those in women with normal blood glucose [8]. Zhu et al. reported that a history of GDM was associated with long-term hip fracture risk and overall fracture risk, but not with calcaneal BMD as measured by ultrasonography [9].

The association between the history of GDM and BMD or osteoporosis requires further investigation. Trabecular bone score (TBS) is a DEXA image-based gray scale structural index that reflects bone microstructure and helps to predict fracture independently of BMD [10]. Previous investigators found significant lower TBS values in DM patients [11, 12]. However, studies on the relationship between DM and TBS have been inconsistent. A study in Korea found that TBS was lower in men with DM than in men without DM; but in women, the observation was not observed [11].

Consequently, a thorough assessment of the relationship between a history of GDM and TBS in postmenopausal women is required.

Herein, the objective of the study was to investigate the association between a history of GDM and osteoporosis, BMD, and TBS in postmenopausal women.

Source: Background Source: Background Source: Background

Study methods

What methods does the paper describe?

Study design and participants

This study was a cross-sectional study. The data were obtained from a cross-sectional survey-the National Health and Nutrition Examination Survey (NHANES), a large, comprehensive, and regularly updated sample of the non-hospitalized U.S. population [13]. Every 2 years, the National Health and Nutrition Examination Survey (NHANES) gathers information to assess the health and nutritional status of Americans. The database included information on the research population’s demographics, physical examination, laboratory test results, nutrition, and questionnaires [13]. This study collected data from 2007 to 2010, 2013 to 2014, and 2017 to 2018.

Inclusion criteria were: (1) postmenopausal women; (2) those with the assessment of BMD; (3) those who had a history of GDM assessed in the NHANES database. Participants with missing information on key covariates were excluded. The study was performed in accordance with the Declaration of Helsinki, and approved by the National Center for Health Statistics (NCHS) Ethics Review Board (ERB) (Continuation of Protocol #2005-06; continuation of Protocol #2005-06; continuation of Protocol #2011-17; Protocol Code #2018-01, effective beginning October 26, 2017; continuation of Protocol Code #2011-17, effective through 26 October 2017).Thus, the requirement of ethical approval for this was waived by the Institutional Review Board of Huai’an maternal and child health care center.

Written informed consent was not required as this study was based on publicly available data. All methods were performed in accordance with the relevant guidelines and regulations.

Data collection

Data were collected including age (years), race/ethnicity, educational level, marital status, poverty income ratio (PIR), alcohol and smoking status, physical activity, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, body mass index (BMI), cords-25-hydroxyvitamin D2 (25OHD2) + 25OHD3 (nmol/L), energy/day (kcal), serum vitamin D (mcg), osteoporosis, total femoral BMD (gm/cm2), femoral neck BMD (gm/cm2), TBS (bone degeneration, no bone degeneration, and unknown).

Race/ethnicity was categorized as Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, and other races including multiracial. Educational level was identified as less than 9th grade, 9th: 11th grade, high school grade/general educational development (GED) or equivalent, some college or AA degree, and college graduate or above. Smoking status was categorized into yes and no based on the following questions: Have you smoked at least 100 cigarettes in your entire life?” and “Do you now smoke cigarettes?”. Alcohol consumption identification was based on answers to questions regarding having had at least 12 drinks in the past year (ALQ101) or drinking more than 12 drinks in a lifetime (ALQ110).

Using the formula BMI = weight (kg)/height (m)2 to determine BMI. Physical activity was evaluated by determining the MET (Met*min). Alcohol status, smoking status, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, and anti-osteoporosis therapy were classifies as yes versus no.

Measurements and outcomes

A history of GDM was identified using the questions “During your pregnancy, were you ever told by a doctor, or other health professional that you had DM, sugar DM, or GDM?”, and “How old were you when you were first told you had DM during a pregnancy?”. Women who answered yes to the question were considered to have a history of GDM. Women were identified as developing DM if they reported having a diagnosis of DM (other than during pregnancy) or, or if they had a haemoglobin (A1C) level was ≥ 6.5%, a fasting plasma glucose level ≥ 126 mg/dL, or 2-h plasma glucose level ≥ 200 mg/dL if they had not previously been diagnosed with DM [13].

The primary outcome of the study was osteoporosis. The secondary outcomes were total femoral BMD, femoral neck BMD, and total TBS. Osteoporosis was determined based on total femoral BMD (gm/cm2) < 0.64 or femoral neck BMD (gm/cm2) < 0.56. Total femoral BMD and femoral neck BMD were measured using a dual energy X-ray absorptiometry (DEXA) scan.

Statistical analysis

Continuous data were described by mean and standard error Mean (S.E), and the comparisons between groups were made by weighted T-test (R package “survey”: “svyttest”). Enumeration data were described in terms of case size and component ratio (N(%)), and the χ2 test was used for comparison between groups (R package “survey”: “svychisq”). Data cleaning, data processing, and statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA), and R version 4.2.0 (2022-04-22 ucrt).

For the dichotomous outcomes of osteoporosis, weighted univariate and multivariate logistic regression models were used to explore the association between GDM and osteoporosis. For total femoral BMD, femoral neck BMD, and total TBS, weighted univariate linear regression and weighted multivariate linear regression models were applied to investigate the association between GDM and total femoral BMD, femoral neck BMD, and total TBS. For the outcome of osteoporosis, the multiple logistic regression model adjusted for age, education, marital status, PIR, alcohol status, previous fracture, parental fracture, and BMI; for total femoral BMD, age, race, education, marital status, PIR, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, BMI, serum vitamin D, and energy were adjusted for; for femoral neck BMD, age, race, marital status, previous fracture, parental fracture, anti-osteoporosis therapy, and BMI were adjusted for; for total TBS, age, race, education, PIR, alcohol status, hypertension, DM, previous fracture, and vitamin D were adjusted for.

Subgroup analyses were conducted to further examine the association between GDM and osteoporosis. The evaluation indexes were odds ratio (OR), and 95% confidence interval (CI). Alpha = 0.05, a P < 0.05 was considered statistically significant.

Source: Methods Source: Methods Source: Methods Source: Methods

Baseline characteristics of included participants

Results: Baseline characteristics of included participants

Based on the inclusion and exclusion criteria, 6732 women were included in this study. The flow chart of the data collection is shown in Fig. 1. Of the 6732 women, 253 women (3.76%) were with GDM. The mean age of the included women was 65.76 (0.28) years, with the majority of women (82.99%) being of non-Hispanic White race/ethnicity. Significant differences in age, education level, smoking status, DM, BMI, and osteoporosis were observed between women with GDM and those without GDM (P > 0.05 for each).

Table 1 shows the characteristics of the study participants.

Fig. 1

The diagram flow of the data collection

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 1

Basic characteristics of the study participants

VariablesTotal (n = 6732)GDMStatisticsP
Yes (n = 253)No (n = 6479)
Age, years, Mean (S.E)65.76 (0.28)62.65 (1.51)65.89 (0.29)t = − 2.11
Race/ethnicity, n (%)χ2 = 0.5060.973
 Mexican American653 (3.02)36 (3.79)617 (2.98)
 Other Hispanic598 (3.15)28 (3.93)570 (3.12)
 Non-Hispanic White4052 (82.99)121 (80.80)3931 (83.08)
 Non-Hispanic Black923 (5.81)37 (6.04)886 (5.80)
 Other race-including multi-racial506 (5.03)31 (5.43)475 (5.01)
Education level, n (%)χ2 = 21.365< 0.001
 Less than 9th grade469 (2.81)17 (2.26)452 (2.83)
 9 to 11th grade791 (8.76)12 (3.07)779 (9.00)
 High school grade/GED or equivalent1737 (25.93)37 (10.08)1700 (26.58)
 Some college or AA degree2195 (33.90)140 (61.35)2055 (32.77)
 College graduate or above1540 (28.60)47 (23.24)1493 (28.82)
Marital status, n (%)χ2 = 0.1460.702
 Married3436 (59.11)149 (54.19)3287 (59.32)
 Other (widowed, divorced, separated, never married, living with partner)3296 (40.89)104 (45.81)3192 (40.68)
Ratio of family income to poverty, Mean3.33 (0.08)3.84 (0.31)3.31 (0.07)t = 1.770.082
Alcohol status, n (%)χ2 = 2.1900.139
 Yes2626 (29.60)79 (19.26)2547 (30.03)
 No4106 (70.40)174 (80.74)3932 (69.97)
Smoked at least 100 cigarettes in lifeχ2 = 2.8230.093
 Yes2659 (39.09)87 (25.41)2572 (39.65)
 No4073 (60.91)166 (74.59)3907 (60.35)
MET, Met*min, Mean (S.E)579.38 (67.29)292.11 (87.14)591.23 (70.17)t = − 2.630.011
Hypertension, n (%)χ2 = 2.6740.102
 No1645 (28.95)49 (16.57)1596 (29.46)
 Yes5087 (71.05)204 (83.43)4883 (70.54)
DM, n (%)χ2 = 29.385< 0.001
 Yes5247 (81.96)101 (39.11)5146 (83.73)
 No1485 (18.04)152 (60.89)1333 (16.27)
Broken or fractured a hip, n (%)χ2 = 1.7010.192
 Yes182 (2.52)6 (7.52)176 (2.31)
 No6550 (97.48)247 (92.48)6303 (97.69)
Parental fracture, n (%)χ2 = 1.2050.272
 No5892 (84.55)225 (71.94)5667 (85.07)
 Yes840 (15.45)28 (28.06)812 (14.93)
Glucocorticoid use, n (%)χ2 = 3.7230.054
 No6076 (89.48)219 (69.93)5857 (90.29)
 Yes656 (10.52)34 (30.07)622 (9.71)
Anti-osteoporosis therapy, n (%)χ2 = 1.9250.165
 No5696 (84.66)212 (67.69)5484 (85.36)
 Yes1036 (15.34)41 (32.31)995 (14.64)
BMI, kg/m2, Mean (S.E)28.49 (0.25)33.37 (2.20)28.29 (0.23)t = 2.310.024
25OHD2 + 25OHD3, nmol/L, Mean (S.E)90.85 (1.75)83.71 (4.16)91.14 (1.74)t = − 1.990.051
Calcium, mg, Mean (S.E)1693.75 (29.74)1887.31 (154.33)1685.76 (30.14)t = 1.300.198
Energy, kcal, Mean (S.E)3383.99 (49.15)3765.67 (193.91)3368.24 (50.89)t = 1.970.053
Vitamin D, mcg, Mean (S.E)8.46 (0.23)9.25 (0.82)8.43 (0.24)t = 0.930.354
Osteoporosis, n (%)χ2 = 7.4720.006
 No5888 (87.62)218 (62.45)5670 (88.66)
 Yes844 (12.38)35 (37.55)809 (11.34)
Total femoral BMD, gm/cm2, Mean (S.E)0.84 (0.00)0.85 (0.03)0.84 (0.00)t = 0.340.737
Femoral neck BMD, gm/cm2, Mean (S.E)0.70 (0.01)0.60 (0.10)0.71 (0.00)t = − 1.100.276
TBS, n (%)χ2 = 9.0740.011
 No bone degeneration791 (11.09)17 (2.74)774 (11.43)
 Bone degeneration740 (7.54)6 (2.65)734 (7.74)
 Unknown5201 (81.37)230 (94.61)4971 (80.83)

GDM: gestational diabetes mellitus; GED: general educational development; DM: diabetes mellitus; BMI: body mass index; BMD: bone mineral density; T: weighted T test; χ2: χ2 test

Source: Baseline characteristics of included participants Source: Baseline characteristics of included participants Source: Baseline characteristics of included participants

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

Results: Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

The result of the unadjusted model showed that women with a history of GDM had a higher risk of osteoporosis (OR: 4.82, 95% CI 1.35 to 17.21, P = 0.018). From the model adjusting for variables, a history of GDM was associated with postmenopausal osteoporosis (OR: 11.18, 95% CI 3.64 to 34.27, P < 0.001). The association between GDM and osteoporosis is presented in Table 2. However, no associations between GDM and total femoral BMD (β: − 0.04, 95% CI − 0.08 to 0.01, P = 0.079), femoral neck BMD (β: − 0.13, 95% CI − 0.29 to 0.03, P = 0.118), and total TBS (β: − 0.04, 95% CI − 0.17 to 0.10, P = 0.588) were observed.

Table 2

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

OutcomesVariablesModel 1Model 2
OR/β (95% CI)POR (95% CI)P
OsteoporosisGDM (Yes)4.82 (1.35 to 17.21)0.01811.18 (3.64 to 34.27)< 0.001
Total femoral BMDGDM (Yes)0.01 (− 0.04 to 0.06)0.348− 0.04 (− 0.08 to 0.01)0.079
Femoral neck BMDGDM (Yes)− 0.11 (− 0.32 to 0.09)0.273− 0.13 (− 0.29 to 0.03)0.118
Total TBSGDM (Yes)− 0.08 (− 0.26 to 0.09)0.362− 0.04 (− 0.17 to 0.10)0.588

Model 1 is an unadjusted model; for the outcome of osteoporosis, model 2 adjusted for age, education, marital status, PIR, alcohol status, previous fracture, parental fracture, and BMI; for total femoral BMD, age, race, education, marital status, PIR, hypertension, diabetes, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, BMI, serum vitamin D, and energy were adjusted for; for femoral neck BMD, age, race, marital status, previous fracture, parental fracture, anti-osteoporosis therapy, and BMI were adjusted for; for total TBS, age, race, education, PIR, alcohol status, hypertension, DM, previous fracture, and vitamin D were adjusted for

GDM gestational diabetes mellitus, BMD bone mineral density, TBS trabecular bone score, OR odds ratio, CI confidence interval

Source: Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS Source: Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

Subgroup analysis of associations between GDM and osteoporosis

Results: Subgroup analysis of associations between GDM and osteoporosis

The result of the subgroup analysis indicated that a history of GDM was related to osteoporosis in postmenopausal women aged ≥ 65 years (OR: 14.21, 95% CI 2.64 to 76.35, P = 0.003) or aged < 65 years (OR: 5.16, 95% CI 1.07 to 24.8, P = 0.046). There was no significant difference between a history of GDM and osteoporosis among postmenopausal women with normal weight (OR: 8.12, 95% CI 0.53 to 123.41, P = 0.138) and overweight (OR: 0.32, 95% CI 0.05 to 2.13, P = 0.245).

However, among postmenopausal women with obesity, an association between a history of GDM and osteoporosis was observed (OR: 26.57, 95% CI 10.23 to 68.98, P < 0.001). A history of GDM was associated with postmenopausal osteoporosis, regardless of whether the women had DM (OR: 13.92, 95% CI 3-63.58, P < 0.001) had not (OR: 7.42, 95% CI 1 to 89.17, P = 0.006). The subgroup analysis of associations between GDM and osteoporosis is shown in Table 3.

Table 3

Subgroup analysis of associations between GDM and osteoporosis

SubgroupsOR (95% CI)P
Age
 ≥ 6514.21 (2.64 to 76.35)0.003
 < 655.16 (1.07 to 24.82)0.046
BMI
 Normal8.12 (0.53 to 123.41)0.138
 Overweight0.32 (0.05 to 2.13)0.245
 Obesity26.57 (10.23 to 68.98)< 0.001
DM
 Yes13.92 (3.62 to 53.58)< 0.001
 No7.42 (1.89 to 29.17)0.006

Age, education, marriage, PIR, alcohol status, previous fracture, parental fracture, and BMI were adjusted for

GDM gestational diabetes mellitus, CI confidence interval, OR odds ratio, DM diabetes mellitus, BMI body mass index

Source: Subgroup analysis of associations between GDM and osteoporosis Source: Subgroup analysis of associations between GDM and osteoporosis

Discussion

Postmenopausal women are considered to be at high risk of developing osteoporosis [14], so evaluation of factors related to BMD, TBS, osteoporosis may help to develop preventive strategies for DM-related bone changes. We found no significant difference in total femoral BMD, femoral neck BMD, and total TBS between postmenopausal women with and without a history of GDM, but, a history of GDM was associated with a higher risk of osteoporosis among postmenopausal women. There was no significant difference between a history of GDM and osteoporosis in postmenopausal women with a normal weight and overweight women.

However, there was an association between a history of GDM and osteoporosis in postmenopausal obese women.

Both DM and osteoporosis are increasing health problems worldwide [15]. Having type 2 DM (T2DM) has been reported as a risk factor for osteoporosis and osteoporotic fractures [15]. Wang et al. demonstrated that poor glycemic control was related to lower levels of bone formation, which may increase the risk of bone fracture in postmenopausal women with T2DM [16]. Karimifar et al. found that osteopenia and osteoporosis are more common in diabetic postmenopausal women compared to non-diabetic postmenopausal women [17].

In this study, a history of GDM was associated with higher osteoporosis risk in postmenopausal women. Regarding the mechanisms between a history of GDM and postmenopausal osteoporosis, several data suggest an effect of advanced glycosylation end products (AGEs) on collagen and bone cells. AGEs accumulating in collagen have been shown to stimulate IL-6 production in human bone cells [18], inhibit osteoblast phenotypic expression, differentiation, and mineralization, inhibit type 1 collagen synthesis, and promote the formation of weak bridges between collagen fibers, resulting in the reduced bone strength and increased osteoclast resorption [19, 20].

Alterations in IGF-1 levels have also been associated with bone abnormalities. IGF-I is also synthesized by osteoblasts and is a regulator of bone cell metabolism [21]. Several studies have shown reduced IGF-1 activity when glucose and AGE levels are high, suggesting osteoblastic resistance to the effects of IGF-1 [22, 23]. Additionally, chronic inflammation may also link the bone abnormalities in DM [24]. Inflammation induced by obesity inhibits the synthesis and secretion of adiponectin from adipose tissue, which may have consequences on bone metabolism [25].

We did not find an association between GDM and total femoral BMD, femoral neck BMD, and total TBS. However, a previous study by Ma et al. reported that the BMD levels in the GDM group were lower than in the normal group [26]. The association between GDM and BMD of the total femoral, BMD of the femoral neck, and total TBS needs to be further investigated.

There was no association between a history of GDM and osteoporosis in postmenopausal normal and overweight women, but there was an association between a history of GDM and osteoporosis in postmenopausal obese women. Previous studies have suggested a positive association between BMI and BMD [27, 28]. A Mexican study of postmenopausal women with normal weight, overweight or varying degrees of obesity found a positive and significant association between BMI and lumbar, total hip, and femoral neck BMD [28].

Obesity has effects on a number of hormones known to act on bone, and so may act on bone through endocrine pathways. Adipocytes express aromatase as the main source of estrogen in postmenopausal women [29]. High fat mass is associated with higher circulating estradiol, so aromatase activity is likely to contribute to the beneficial effects of fat on bone, particularly in postmenopausal women. Pancreatic and gut hormone secretion is altered in obesity and may influence bone metabolism. Insulin, amylin, and pepsin are increased in obesity and may have direct effects on bone cells to increase bone formation and decrease resorption.

Insulin may also have indirect beneficial effects on bone by decreasing hepatic sex hormone-binding globulin production, which increases the bioavailability of estrogen and androgens [30]. Promoting a healthy lifestyle and reducing BMI in women with GDM may be justified to improve bone health and prevent future osteoporosis.

Based on the population-representative database of NHANES, this study explored the association between the history of GDM and BMD, TBS, and the risk of osteoporosis in postmenopausal women, which filled the gap in related fields to a certain extent. Understanding the factors associated with BMD and osteoporosis risk in postmenopausal women with a history of GDM has important implications for medical plans and individual patients. Nonetheless, the study does have its limitations. First, the history of GDM in this study was obtained by a self-reported doctor-diagnosed GDM, which inevitably has a certain recall bias.

Second, the cross-sectional nature of the survey limits our ability to identify aetiological factors. Third, the detection data of TBS in the database are limited, and the proportion of GDM in the population with TBS is extremely low. Therefore, prospective and large-sample studies are needed to further investigate the effect of a history of GDM on TBS.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Baseline characteristics of included participants

Based on the inclusion and exclusion criteria, 6732 women were included in this study. The flow chart of the data collection is shown in Fig. 1. Of the 6732 women, 253 women (3.76%) were with GDM. The mean age of the included women was 65.76 (0.28) years, with the majority of women (82.99%) being of non-Hispanic White race/ethnicity. Significant differences in age, education level, smoking status, DM, BMI, and osteoporosis were observed between women with GDM and those without GDM (P > 0.05 for each).

Table 1 shows the characteristics of the study participants.

Fig. 1

The diagram flow of the data collection

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 1

Basic characteristics of the study participants

VariablesTotal (n = 6732)GDMStatisticsP
Yes (n = 253)No (n = 6479)
Age, years, Mean (S.E)65.76 (0.28)62.65 (1.51)65.89 (0.29)t = − 2.11
Race/ethnicity, n (%)χ2 = 0.5060.973
 Mexican American653 (3.02)36 (3.79)617 (2.98)
 Other Hispanic598 (3.15)28 (3.93)570 (3.12)
 Non-Hispanic White4052 (82.99)121 (80.80)3931 (83.08)
 Non-Hispanic Black923 (5.81)37 (6.04)886 (5.80)
 Other race-including multi-racial506 (5.03)31 (5.43)475 (5.01)
Education level, n (%)χ2 = 21.365< 0.001
 Less than 9th grade469 (2.81)17 (2.26)452 (2.83)
 9 to 11th grade791 (8.76)12 (3.07)779 (9.00)
 High school grade/GED or equivalent1737 (25.93)37 (10.08)1700 (26.58)
 Some college or AA degree2195 (33.90)140 (61.35)2055 (32.77)
 College graduate or above1540 (28.60)47 (23.24)1493 (28.82)
Marital status, n (%)χ2 = 0.1460.702
 Married3436 (59.11)149 (54.19)3287 (59.32)
 Other (widowed, divorced, separated, never married, living with partner)3296 (40.89)104 (45.81)3192 (40.68)
Ratio of family income to poverty, Mean3.33 (0.08)3.84 (0.31)3.31 (0.07)t = 1.770.082
Alcohol status, n (%)χ2 = 2.1900.139
 Yes2626 (29.60)79 (19.26)2547 (30.03)
 No4106 (70.40)174 (80.74)3932 (69.97)
Smoked at least 100 cigarettes in lifeχ2 = 2.8230.093
 Yes2659 (39.09)87 (25.41)2572 (39.65)
 No4073 (60.91)166 (74.59)3907 (60.35)
MET, Met*min, Mean (S.E)579.38 (67.29)292.11 (87.14)591.23 (70.17)t = − 2.630.011
Hypertension, n (%)χ2 = 2.6740.102
 No1645 (28.95)49 (16.57)1596 (29.46)
 Yes5087 (71.05)204 (83.43)4883 (70.54)
DM, n (%)χ2 = 29.385< 0.001
 Yes5247 (81.96)101 (39.11)5146 (83.73)
 No1485 (18.04)152 (60.89)1333 (16.27)
Broken or fractured a hip, n (%)χ2 = 1.7010.192
 Yes182 (2.52)6 (7.52)176 (2.31)
 No6550 (97.48)247 (92.48)6303 (97.69)
Parental fracture, n (%)χ2 = 1.2050.272
 No5892 (84.55)225 (71.94)5667 (85.07)
 Yes840 (15.45)28 (28.06)812 (14.93)
Glucocorticoid use, n (%)χ2 = 3.7230.054
 No6076 (89.48)219 (69.93)5857 (90.29)
 Yes656 (10.52)34 (30.07)622 (9.71)
Anti-osteoporosis therapy, n (%)χ2 = 1.9250.165
 No5696 (84.66)212 (67.69)5484 (85.36)
 Yes1036 (15.34)41 (32.31)995 (14.64)
BMI, kg/m2, Mean (S.E)28.49 (0.25)33.37 (2.20)28.29 (0.23)t = 2.310.024
25OHD2 + 25OHD3, nmol/L, Mean (S.E)90.85 (1.75)83.71 (4.16)91.14 (1.74)t = − 1.990.051
Calcium, mg, Mean (S.E)1693.75 (29.74)1887.31 (154.33)1685.76 (30.14)t = 1.300.198
Energy, kcal, Mean (S.E)3383.99 (49.15)3765.67 (193.91)3368.24 (50.89)t = 1.970.053
Vitamin D, mcg, Mean (S.E)8.46 (0.23)9.25 (0.82)8.43 (0.24)t = 0.930.354
Osteoporosis, n (%)χ2 = 7.4720.006
 No5888 (87.62)218 (62.45)5670 (88.66)
 Yes844 (12.38)35 (37.55)809 (11.34)
Total femoral BMD, gm/cm2, Mean (S.E)0.84 (0.00)0.85 (0.03)0.84 (0.00)t = 0.340.737
Femoral neck BMD, gm/cm2, Mean (S.E)0.70 (0.01)0.60 (0.10)0.71 (0.00)t = − 1.100.276
TBS, n (%)χ2 = 9.0740.011
 No bone degeneration791 (11.09)17 (2.74)774 (11.43)
 Bone degeneration740 (7.54)6 (2.65)734 (7.74)
 Unknown5201 (81.37)230 (94.61)4971 (80.83)

GDM: gestational diabetes mellitus; GED: general educational development; DM: diabetes mellitus; BMI: body mass index; BMD: bone mineral density; T: weighted T test; χ2: χ2 test

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

The result of the unadjusted model showed that women with a history of GDM had a higher risk of osteoporosis (OR: 4.82, 95% CI 1.35 to 17.21, P = 0.018). From the model adjusting for variables, a history of GDM was associated with postmenopausal osteoporosis (OR: 11.18, 95% CI 3.64 to 34.27, P < 0.001). The association between GDM and osteoporosis is presented in Table 2. However, no associations between GDM and total femoral BMD (β: − 0.04, 95% CI − 0.08 to 0.01, P = 0.079), femoral neck BMD (β: − 0.13, 95% CI − 0.29 to 0.03, P = 0.118), and total TBS (β: − 0.04, 95% CI − 0.17 to 0.10, P = 0.588) were observed.

Table 2

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

OutcomesVariablesModel 1Model 2
OR/β (95% CI)POR (95% CI)P
OsteoporosisGDM (Yes)4.82 (1.35 to 17.21)0.01811.18 (3.64 to 34.27)< 0.001
Total femoral BMDGDM (Yes)0.01 (− 0.04 to 0.06)0.348− 0.04 (− 0.08 to 0.01)0.079
Femoral neck BMDGDM (Yes)− 0.11 (− 0.32 to 0.09)0.273− 0.13 (− 0.29 to 0.03)0.118
Total TBSGDM (Yes)− 0.08 (− 0.26 to 0.09)0.362− 0.04 (− 0.17 to 0.10)0.588

Model 1 is an unadjusted model; for the outcome of osteoporosis, model 2 adjusted for age, education, marital status, PIR, alcohol status, previous fracture, parental fracture, and BMI; for total femoral BMD, age, race, education, marital status, PIR, hypertension, diabetes, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, BMI, serum vitamin D, and energy were adjusted for; for femoral neck BMD, age, race, marital status, previous fracture, parental fracture, anti-osteoporosis therapy, and BMI were adjusted for; for total TBS, age, race, education, PIR, alcohol status, hypertension, DM, previous fracture, and vitamin D were adjusted for

GDM gestational diabetes mellitus, BMD bone mineral density, TBS trabecular bone score, OR odds ratio, CI confidence interval

Subgroup analysis of associations between GDM and osteoporosis

The result of the subgroup analysis indicated that a history of GDM was related to osteoporosis in postmenopausal women aged ≥ 65 years (OR: 14.21, 95% CI 2.64 to 76.35, P = 0.003) or aged < 65 years (OR: 5.16, 95% CI 1.07 to 24.8, P = 0.046). There was no significant difference between a history of GDM and osteoporosis among postmenopausal women with normal weight (OR: 8.12, 95% CI 0.53 to 123.41, P = 0.138) and overweight (OR: 0.32, 95% CI 0.05 to 2.13, P = 0.245).

However, among postmenopausal women with obesity, an association between a history of GDM and osteoporosis was observed (OR: 26.57, 95% CI 10.23 to 68.98, P < 0.001). A history of GDM was associated with postmenopausal osteoporosis, regardless of whether the women had DM (OR: 13.92, 95% CI 3-63.58, P < 0.001) had not (OR: 7.42, 95% CI 1 to 89.17, P = 0.006). The subgroup analysis of associations between GDM and osteoporosis is shown in Table 3.

Table 3

Subgroup analysis of associations between GDM and osteoporosis

SubgroupsOR (95% CI)P
Age
 ≥ 6514.21 (2.64 to 76.35)0.003
 < 655.16 (1.07 to 24.82)0.046
BMI
 Normal8.12 (0.53 to 123.41)0.138
 Overweight0.32 (0.05 to 2.13)0.245
 Obesity26.57 (10.23 to 68.98)< 0.001
DM
 Yes13.92 (3.62 to 53.58)< 0.001
 No7.42 (1.89 to 29.17)0.006

Age, education, marriage, PIR, alcohol status, previous fracture, parental fracture, and BMI were adjusted for

GDM gestational diabetes mellitus, CI confidence interval, OR odds ratio, DM diabetes mellitus, BMI body mass index

Source: Results Source: Results Source: Results

Conclusions

A history of GDM was associated with a higher risk of osteoporosis in postmenopausal women, and there was an association between a history of GDM and osteoporosis in postmenopausal women with an obese BMI.

Source: Conclusions
Authors’ abstract

Background

Studies on the association of gestational diabetes mellitus (GDM) with osteoporosis, and bone mineral density (BMD) have been inconsistent. The aim of this study was to investigate the association of a history of GDM with osteoporosis, BMD, and trabecular bone score (TBS) in postmenopausal women.

Methods

Postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) between 2007 and 2010, between 2013 and 2014, and between 2017 and 2018 were retrospectively included in this cross-sectional study. The logistic regression model was used to explore the relationship between GDM and osteoporosis, and a weighted linear regression model was applied to investigate the association between GDM and total femoral BMD, femoral neck BMD, and total TBS. Subgroup analysis of the association between GDM and osteoporosis was performed according to age, body mass index (BMI), and DM (yes or no).

Results

Of the 6732 women included, 253 women (3.76%) had GDM. No significant differences in total femoral BMD, femoral neck BMD, and total TBS were observed between postmenopausal women with and without a history of GDM. However, a history of GDM was associated with a higher risk of osteoporosis in postmenopausal women [odds ratio (OR): 11.18, 95% confidence intervals (CI): 3.64 to 34.27, P < 0.001]. There was no significant difference between a history of GDM and osteoporosis in postmenopausal women whom BMI is normal and overweight women.

However, there was an association between a history of GDM and osteoporosis in postmenopausal obese women (OR: 26.57, 95% CI 10.23 to 68.98, P < 0.001).

Conclusion

A history of GDM was associated with a higher risk of osteoporosis in postmenopausal women, particularly in postmenopausal obese women.

Read the full paper

Background

Osteoporosis is a musculoskeletal disease characterized by loss of bone mass and bone microstructure damage [1]. Postmenopausal women experience a steady loss of bone mass due to aging and hormonal changes, leading to osteoporosis [2]. More than 10 million Americans over the age of 50 years suffer from osteoporosis, and this number is expected to increase in the future with the expected growth of the elderly population [3]. Each year, osteoporosis results in more than 9 million fractures worldwide [4].

Osteoporotic fractures in postmenopausal women are associated with poor quality of life and reduced life expectancy [5]. The gold standard for diagnosing osteoporosis is the measurement of bone mineral density (BMD) using a dual-energy X-ray absorptiometry (DEXA) scan. Given the damage caused by osteoporosis and the fact that BMD is a significant marker of bone mass, it is necessary to identify factors associated with BMD and osteoporosis.

Diabetes mellitus (DM) has been recognized as one of the risk factors for osteoporotic fractures [6]. Gestational DM (GDM), a common complication of pregnancy, is defined as glucose intolerance that first diagnosed during pregnancy [7]. BMD in women with GDM was reported to be lower than those in women with normal blood glucose [8]. Zhu et al. reported that a history of GDM was associated with long-term hip fracture risk and overall fracture risk, but not with calcaneal BMD as measured by ultrasonography [9].

The association between the history of GDM and BMD or osteoporosis requires further investigation. Trabecular bone score (TBS) is a DEXA image-based gray scale structural index that reflects bone microstructure and helps to predict fracture independently of BMD [10]. Previous investigators found significant lower TBS values in DM patients [11, 12]. However, studies on the relationship between DM and TBS have been inconsistent. A study in Korea found that TBS was lower in men with DM than in men without DM; but in women, the observation was not observed [11].

Consequently, a thorough assessment of the relationship between a history of GDM and TBS in postmenopausal women is required.

Herein, the objective of the study was to investigate the association between a history of GDM and osteoporosis, BMD, and TBS in postmenopausal women.

Methods

Study design and participants

This study was a cross-sectional study. The data were obtained from a cross-sectional survey-the National Health and Nutrition Examination Survey (NHANES), a large, comprehensive, and regularly updated sample of the non-hospitalized U.S. population [13]. Every 2 years, the National Health and Nutrition Examination Survey (NHANES) gathers information to assess the health and nutritional status of Americans. The database included information on the research population’s demographics, physical examination, laboratory test results, nutrition, and questionnaires [13]. This study collected data from 2007 to 2010, 2013 to 2014, and 2017 to 2018.

Inclusion criteria were: (1) postmenopausal women; (2) those with the assessment of BMD; (3) those who had a history of GDM assessed in the NHANES database. Participants with missing information on key covariates were excluded. The study was performed in accordance with the Declaration of Helsinki, and approved by the National Center for Health Statistics (NCHS) Ethics Review Board (ERB) (Continuation of Protocol #2005-06; continuation of Protocol #2005-06; continuation of Protocol #2011-17; Protocol Code #2018-01, effective beginning October 26, 2017; continuation of Protocol Code #2011-17, effective through 26 October 2017).Thus, the requirement of ethical approval for this was waived by the Institutional Review Board of Huai’an maternal and child health care center.

Written informed consent was not required as this study was based on publicly available data. All methods were performed in accordance with the relevant guidelines and regulations.

Data collection

Data were collected including age (years), race/ethnicity, educational level, marital status, poverty income ratio (PIR), alcohol and smoking status, physical activity, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, body mass index (BMI), cords-25-hydroxyvitamin D2 (25OHD2) + 25OHD3 (nmol/L), energy/day (kcal), serum vitamin D (mcg), osteoporosis, total femoral BMD (gm/cm2), femoral neck BMD (gm/cm2), TBS (bone degeneration, no bone degeneration, and unknown).

Race/ethnicity was categorized as Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, and other races including multiracial. Educational level was identified as less than 9th grade, 9th: 11th grade, high school grade/general educational development (GED) or equivalent, some college or AA degree, and college graduate or above. Smoking status was categorized into yes and no based on the following questions: Have you smoked at least 100 cigarettes in your entire life?” and “Do you now smoke cigarettes?”. Alcohol consumption identification was based on answers to questions regarding having had at least 12 drinks in the past year (ALQ101) or drinking more than 12 drinks in a lifetime (ALQ110).

Using the formula BMI = weight (kg)/height (m)2 to determine BMI. Physical activity was evaluated by determining the MET (Met*min). Alcohol status, smoking status, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, and anti-osteoporosis therapy were classifies as yes versus no.

Measurements and outcomes

A history of GDM was identified using the questions “During your pregnancy, were you ever told by a doctor, or other health professional that you had DM, sugar DM, or GDM?”, and “How old were you when you were first told you had DM during a pregnancy?”. Women who answered yes to the question were considered to have a history of GDM. Women were identified as developing DM if they reported having a diagnosis of DM (other than during pregnancy) or, or if they had a haemoglobin (A1C) level was ≥ 6.5%, a fasting plasma glucose level ≥ 126 mg/dL, or 2-h plasma glucose level ≥ 200 mg/dL if they had not previously been diagnosed with DM [13].

The primary outcome of the study was osteoporosis. The secondary outcomes were total femoral BMD, femoral neck BMD, and total TBS. Osteoporosis was determined based on total femoral BMD (gm/cm2) < 0.64 or femoral neck BMD (gm/cm2) < 0.56. Total femoral BMD and femoral neck BMD were measured using a dual energy X-ray absorptiometry (DEXA) scan.

Statistical analysis

Continuous data were described by mean and standard error Mean (S.E), and the comparisons between groups were made by weighted T-test (R package “survey”: “svyttest”). Enumeration data were described in terms of case size and component ratio (N(%)), and the χ2 test was used for comparison between groups (R package “survey”: “svychisq”). Data cleaning, data processing, and statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA), and R version 4.2.0 (2022-04-22 ucrt).

For the dichotomous outcomes of osteoporosis, weighted univariate and multivariate logistic regression models were used to explore the association between GDM and osteoporosis. For total femoral BMD, femoral neck BMD, and total TBS, weighted univariate linear regression and weighted multivariate linear regression models were applied to investigate the association between GDM and total femoral BMD, femoral neck BMD, and total TBS. For the outcome of osteoporosis, the multiple logistic regression model adjusted for age, education, marital status, PIR, alcohol status, previous fracture, parental fracture, and BMI; for total femoral BMD, age, race, education, marital status, PIR, hypertension, DM, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, BMI, serum vitamin D, and energy were adjusted for; for femoral neck BMD, age, race, marital status, previous fracture, parental fracture, anti-osteoporosis therapy, and BMI were adjusted for; for total TBS, age, race, education, PIR, alcohol status, hypertension, DM, previous fracture, and vitamin D were adjusted for.

Subgroup analyses were conducted to further examine the association between GDM and osteoporosis. The evaluation indexes were odds ratio (OR), and 95% confidence interval (CI). Alpha = 0.05, a P < 0.05 was considered statistically significant.

Results

Baseline characteristics of included participants

Based on the inclusion and exclusion criteria, 6732 women were included in this study. The flow chart of the data collection is shown in Fig. 1. Of the 6732 women, 253 women (3.76%) were with GDM. The mean age of the included women was 65.76 (0.28) years, with the majority of women (82.99%) being of non-Hispanic White race/ethnicity. Significant differences in age, education level, smoking status, DM, BMI, and osteoporosis were observed between women with GDM and those without GDM (P > 0.05 for each).

Table 1 shows the characteristics of the study participants.

Fig. 1

The diagram flow of the data collection

Figure image at the original source: open the original paper. This file is not included in this text import.

Table 1

Basic characteristics of the study participants

VariablesTotal (n = 6732)GDMStatisticsP
Yes (n = 253)No (n = 6479)
Age, years, Mean (S.E)65.76 (0.28)62.65 (1.51)65.89 (0.29)t = − 2.11
Race/ethnicity, n (%)χ2 = 0.5060.973
 Mexican American653 (3.02)36 (3.79)617 (2.98)
 Other Hispanic598 (3.15)28 (3.93)570 (3.12)
 Non-Hispanic White4052 (82.99)121 (80.80)3931 (83.08)
 Non-Hispanic Black923 (5.81)37 (6.04)886 (5.80)
 Other race-including multi-racial506 (5.03)31 (5.43)475 (5.01)
Education level, n (%)χ2 = 21.365< 0.001
 Less than 9th grade469 (2.81)17 (2.26)452 (2.83)
 9 to 11th grade791 (8.76)12 (3.07)779 (9.00)
 High school grade/GED or equivalent1737 (25.93)37 (10.08)1700 (26.58)
 Some college or AA degree2195 (33.90)140 (61.35)2055 (32.77)
 College graduate or above1540 (28.60)47 (23.24)1493 (28.82)
Marital status, n (%)χ2 = 0.1460.702
 Married3436 (59.11)149 (54.19)3287 (59.32)
 Other (widowed, divorced, separated, never married, living with partner)3296 (40.89)104 (45.81)3192 (40.68)
Ratio of family income to poverty, Mean3.33 (0.08)3.84 (0.31)3.31 (0.07)t = 1.770.082
Alcohol status, n (%)χ2 = 2.1900.139
 Yes2626 (29.60)79 (19.26)2547 (30.03)
 No4106 (70.40)174 (80.74)3932 (69.97)
Smoked at least 100 cigarettes in lifeχ2 = 2.8230.093
 Yes2659 (39.09)87 (25.41)2572 (39.65)
 No4073 (60.91)166 (74.59)3907 (60.35)
MET, Met*min, Mean (S.E)579.38 (67.29)292.11 (87.14)591.23 (70.17)t = − 2.630.011
Hypertension, n (%)χ2 = 2.6740.102
 No1645 (28.95)49 (16.57)1596 (29.46)
 Yes5087 (71.05)204 (83.43)4883 (70.54)
DM, n (%)χ2 = 29.385< 0.001
 Yes5247 (81.96)101 (39.11)5146 (83.73)
 No1485 (18.04)152 (60.89)1333 (16.27)
Broken or fractured a hip, n (%)χ2 = 1.7010.192
 Yes182 (2.52)6 (7.52)176 (2.31)
 No6550 (97.48)247 (92.48)6303 (97.69)
Parental fracture, n (%)χ2 = 1.2050.272
 No5892 (84.55)225 (71.94)5667 (85.07)
 Yes840 (15.45)28 (28.06)812 (14.93)
Glucocorticoid use, n (%)χ2 = 3.7230.054
 No6076 (89.48)219 (69.93)5857 (90.29)
 Yes656 (10.52)34 (30.07)622 (9.71)
Anti-osteoporosis therapy, n (%)χ2 = 1.9250.165
 No5696 (84.66)212 (67.69)5484 (85.36)
 Yes1036 (15.34)41 (32.31)995 (14.64)
BMI, kg/m2, Mean (S.E)28.49 (0.25)33.37 (2.20)28.29 (0.23)t = 2.310.024
25OHD2 + 25OHD3, nmol/L, Mean (S.E)90.85 (1.75)83.71 (4.16)91.14 (1.74)t = − 1.990.051
Calcium, mg, Mean (S.E)1693.75 (29.74)1887.31 (154.33)1685.76 (30.14)t = 1.300.198
Energy, kcal, Mean (S.E)3383.99 (49.15)3765.67 (193.91)3368.24 (50.89)t = 1.970.053
Vitamin D, mcg, Mean (S.E)8.46 (0.23)9.25 (0.82)8.43 (0.24)t = 0.930.354
Osteoporosis, n (%)χ2 = 7.4720.006
 No5888 (87.62)218 (62.45)5670 (88.66)
 Yes844 (12.38)35 (37.55)809 (11.34)
Total femoral BMD, gm/cm2, Mean (S.E)0.84 (0.00)0.85 (0.03)0.84 (0.00)t = 0.340.737
Femoral neck BMD, gm/cm2, Mean (S.E)0.70 (0.01)0.60 (0.10)0.71 (0.00)t = − 1.100.276
TBS, n (%)χ2 = 9.0740.011
 No bone degeneration791 (11.09)17 (2.74)774 (11.43)
 Bone degeneration740 (7.54)6 (2.65)734 (7.74)
 Unknown5201 (81.37)230 (94.61)4971 (80.83)

GDM: gestational diabetes mellitus; GED: general educational development; DM: diabetes mellitus; BMI: body mass index; BMD: bone mineral density; T: weighted T test; χ2: χ2 test

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

The result of the unadjusted model showed that women with a history of GDM had a higher risk of osteoporosis (OR: 4.82, 95% CI 1.35 to 17.21, P = 0.018). From the model adjusting for variables, a history of GDM was associated with postmenopausal osteoporosis (OR: 11.18, 95% CI 3.64 to 34.27, P < 0.001). The association between GDM and osteoporosis is presented in Table 2. However, no associations between GDM and total femoral BMD (β: − 0.04, 95% CI − 0.08 to 0.01, P = 0.079), femoral neck BMD (β: − 0.13, 95% CI − 0.29 to 0.03, P = 0.118), and total TBS (β: − 0.04, 95% CI − 0.17 to 0.10, P = 0.588) were observed.

Table 2

Associations of GDM with osteoporosis, total femoral BMD, femoral neck BMD, and total TBS

OutcomesVariablesModel 1Model 2
OR/β (95% CI)POR (95% CI)P
OsteoporosisGDM (Yes)4.82 (1.35 to 17.21)0.01811.18 (3.64 to 34.27)< 0.001
Total femoral BMDGDM (Yes)0.01 (− 0.04 to 0.06)0.348− 0.04 (− 0.08 to 0.01)0.079
Femoral neck BMDGDM (Yes)− 0.11 (− 0.32 to 0.09)0.273− 0.13 (− 0.29 to 0.03)0.118
Total TBSGDM (Yes)− 0.08 (− 0.26 to 0.09)0.362− 0.04 (− 0.17 to 0.10)0.588

Model 1 is an unadjusted model; for the outcome of osteoporosis, model 2 adjusted for age, education, marital status, PIR, alcohol status, previous fracture, parental fracture, and BMI; for total femoral BMD, age, race, education, marital status, PIR, hypertension, diabetes, previous fracture, parental fracture, glucocorticoid use, anti-osteoporosis therapy, BMI, serum vitamin D, and energy were adjusted for; for femoral neck BMD, age, race, marital status, previous fracture, parental fracture, anti-osteoporosis therapy, and BMI were adjusted for; for total TBS, age, race, education, PIR, alcohol status, hypertension, DM, previous fracture, and vitamin D were adjusted for

GDM gestational diabetes mellitus, BMD bone mineral density, TBS trabecular bone score, OR odds ratio, CI confidence interval

Subgroup analysis of associations between GDM and osteoporosis

The result of the subgroup analysis indicated that a history of GDM was related to osteoporosis in postmenopausal women aged ≥ 65 years (OR: 14.21, 95% CI 2.64 to 76.35, P = 0.003) or aged < 65 years (OR: 5.16, 95% CI 1.07 to 24.8, P = 0.046). There was no significant difference between a history of GDM and osteoporosis among postmenopausal women with normal weight (OR: 8.12, 95% CI 0.53 to 123.41, P = 0.138) and overweight (OR: 0.32, 95% CI 0.05 to 2.13, P = 0.245).

However, among postmenopausal women with obesity, an association between a history of GDM and osteoporosis was observed (OR: 26.57, 95% CI 10.23 to 68.98, P < 0.001). A history of GDM was associated with postmenopausal osteoporosis, regardless of whether the women had DM (OR: 13.92, 95% CI 3-63.58, P < 0.001) had not (OR: 7.42, 95% CI 1 to 89.17, P = 0.006). The subgroup analysis of associations between GDM and osteoporosis is shown in Table 3.

Table 3

Subgroup analysis of associations between GDM and osteoporosis

SubgroupsOR (95% CI)P
Age
 ≥ 6514.21 (2.64 to 76.35)0.003
 < 655.16 (1.07 to 24.82)0.046
BMI
 Normal8.12 (0.53 to 123.41)0.138
 Overweight0.32 (0.05 to 2.13)0.245
 Obesity26.57 (10.23 to 68.98)< 0.001
DM
 Yes13.92 (3.62 to 53.58)< 0.001
 No7.42 (1.89 to 29.17)0.006

Age, education, marriage, PIR, alcohol status, previous fracture, parental fracture, and BMI were adjusted for

GDM gestational diabetes mellitus, CI confidence interval, OR odds ratio, DM diabetes mellitus, BMI body mass index

Discussion

Postmenopausal women are considered to be at high risk of developing osteoporosis [14], so evaluation of factors related to BMD, TBS, osteoporosis may help to develop preventive strategies for DM-related bone changes. We found no significant difference in total femoral BMD, femoral neck BMD, and total TBS between postmenopausal women with and without a history of GDM, but, a history of GDM was associated with a higher risk of osteoporosis among postmenopausal women. There was no significant difference between a history of GDM and osteoporosis in postmenopausal women with a normal weight and overweight women.

However, there was an association between a history of GDM and osteoporosis in postmenopausal obese women.

Both DM and osteoporosis are increasing health problems worldwide [15]. Having type 2 DM (T2DM) has been reported as a risk factor for osteoporosis and osteoporotic fractures [15]. Wang et al. demonstrated that poor glycemic control was related to lower levels of bone formation, which may increase the risk of bone fracture in postmenopausal women with T2DM [16]. Karimifar et al. found that osteopenia and osteoporosis are more common in diabetic postmenopausal women compared to non-diabetic postmenopausal women [17].

In this study, a history of GDM was associated with higher osteoporosis risk in postmenopausal women. Regarding the mechanisms between a history of GDM and postmenopausal osteoporosis, several data suggest an effect of advanced glycosylation end products (AGEs) on collagen and bone cells. AGEs accumulating in collagen have been shown to stimulate IL-6 production in human bone cells [18], inhibit osteoblast phenotypic expression, differentiation, and mineralization, inhibit type 1 collagen synthesis, and promote the formation of weak bridges between collagen fibers, resulting in the reduced bone strength and increased osteoclast resorption [19, 20].

Alterations in IGF-1 levels have also been associated with bone abnormalities. IGF-I is also synthesized by osteoblasts and is a regulator of bone cell metabolism [21]. Several studies have shown reduced IGF-1 activity when glucose and AGE levels are high, suggesting osteoblastic resistance to the effects of IGF-1 [22, 23]. Additionally, chronic inflammation may also link the bone abnormalities in DM [24]. Inflammation induced by obesity inhibits the synthesis and secretion of adiponectin from adipose tissue, which may have consequences on bone metabolism [25].

We did not find an association between GDM and total femoral BMD, femoral neck BMD, and total TBS. However, a previous study by Ma et al. reported that the BMD levels in the GDM group were lower than in the normal group [26]. The association between GDM and BMD of the total femoral, BMD of the femoral neck, and total TBS needs to be further investigated.

There was no association between a history of GDM and osteoporosis in postmenopausal normal and overweight women, but there was an association between a history of GDM and osteoporosis in postmenopausal obese women. Previous studies have suggested a positive association between BMI and BMD [27, 28]. A Mexican study of postmenopausal women with normal weight, overweight or varying degrees of obesity found a positive and significant association between BMI and lumbar, total hip, and femoral neck BMD [28].

Obesity has effects on a number of hormones known to act on bone, and so may act on bone through endocrine pathways. Adipocytes express aromatase as the main source of estrogen in postmenopausal women [29]. High fat mass is associated with higher circulating estradiol, so aromatase activity is likely to contribute to the beneficial effects of fat on bone, particularly in postmenopausal women. Pancreatic and gut hormone secretion is altered in obesity and may influence bone metabolism. Insulin, amylin, and pepsin are increased in obesity and may have direct effects on bone cells to increase bone formation and decrease resorption.

Insulin may also have indirect beneficial effects on bone by decreasing hepatic sex hormone-binding globulin production, which increases the bioavailability of estrogen and androgens [30]. Promoting a healthy lifestyle and reducing BMI in women with GDM may be justified to improve bone health and prevent future osteoporosis.

Based on the population-representative database of NHANES, this study explored the association between the history of GDM and BMD, TBS, and the risk of osteoporosis in postmenopausal women, which filled the gap in related fields to a certain extent. Understanding the factors associated with BMD and osteoporosis risk in postmenopausal women with a history of GDM has important implications for medical plans and individual patients. Nonetheless, the study does have its limitations. First, the history of GDM in this study was obtained by a self-reported doctor-diagnosed GDM, which inevitably has a certain recall bias.

Second, the cross-sectional nature of the survey limits our ability to identify aetiological factors. Third, the detection data of TBS in the database are limited, and the proportion of GDM in the population with TBS is extremely low. Therefore, prospective and large-sample studies are needed to further investigate the effect of a history of GDM on TBS.

Conclusions

A history of GDM was associated with a higher risk of osteoporosis in postmenopausal women, and there was an association between a history of GDM and osteoporosis in postmenopausal women with an obese BMI.

Abbreviations

BMD

Bone mineral density

DEXA

Dual-energy X-ray absorptiometry

GDM

Gestational DM

TBS

Trabecular bone score

NHANES

National Health and Nutrition Examination Survey

PIR

Poverty-to-income ratio

BMI

Body mass index

GED

General educational development

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Not applicable.

Author contributions

BL and LZ designed the study. BL wrote the manuscript. BL and LZ collected, analyzed, and interpreted the data. LZ critically reviewed, edited, and approved the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the NHANES database,https://wwwn.cdc.gov/nchs/nhanes/.

Declarations

Ethics approval and consent to participate

The study was performed in accordance with the Declaration of Helsinki, and approved by the National Center for Health Statistics (NCHS) Ethics Review Board (ERB) (Continuation of Protocol #2005-06; continuation of Protocol #2005-06; continuation of Protocol #2011-17; Protocol Code #2018-01, effective beginning October 26, 2017; continuation of Protocol Code #2011-17, effective through 26 October 2017). Thus, the requirement of ethical approval for this was waived by the Institutional Review Board of Huai’an maternal and child health care center. Written informed consent was not required as this study was based on publicly available data.

All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

References

1. Wu B Zhu XF Yang XQ Wang WY Lu JH Effects of osthole on osteoporotic rats: a systematic review and meta-analysis Pharm Biol 2022 60 1625 1634 10.1080/13880209.2022.2110267 35980123 PMC9397480
2. Jiang B Feng C Li C Tu C Li Z A bibliometric and visualization analysis of glucocorticoid-induced osteoporosis research from 2012 to 2021 Front Endocrinol 2022 13 961471 10.3389/fendo.2022.961471 PMC9388768 35992120
3. Keshishi D Makunts T Abagyan R Common osteoporosis drug associated with increased rates of depression and anxiety Sci Rep 2021 11 23956 10.1038/s41598-021-03214-x 34907232 PMC8671447
4. Borgström F Karlsson L Ortsäter G Norton N Halbout P Cooper C Fragility fractures in Europe: burden, management and opportunities Arch Osteoporos 2020 15 59 10.1007/s11657-020-0706-y 32306163 PMC7166207
5. Lu C Wang L Zhang L Xue C Ye H Chen X Li-doped calcium phosphate cement for accelerated bone regeneration of osteoporotic bone defect J Appl Biomater Funct Mater 2022 20 22808000221099012 36148984 10.1177/22808000221099012
6. Romero-Díaz C Duarte-Montero D Gutiérrez-Romero SA Mendivil CO Diabetes and bone fragility Diabetes Ther 2021 12 71 86 10.1007/s13300-020-00964-1 33185853 PMC7843783
7. Gilbert L Gross J Lanzi S Quansah DY Puder J Horsch A How diet, physical activity and psychosocial well-being interact in women with gestational diabetes mellitus: an integrative review BMC Pregnancy Childbirth 2019 19 60 10.1186/s12884-019-2185-y 30732571 PMC6367798
8. Wang Q Wang C Comparison of the expression levels of TNF-α, IL-6, hsCRP and sICAM-1 inflammatory factors, bone mineral density and nutritional status between diabetic and normal pregnant women Cell Mol Biol 2020 66 132 7 10.14715/cmb/2020.66.3.20 32538759
9. Zhu Y Zhang C Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective Curr Diab Rep 2016 16 7 10.1007/s11892-015-0699-x 26742932 PMC6675405
10. Shevroja E Cafarelli FP Guglielmi G Hans D DXA parameters, trabecular bone score (TBS) and bone mineral density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis Endocrine 2021 74 20 28 10.1007/s12020-021-02806-x 34245432 PMC8440280
11. Kim JH Choi HJ Ku EJ Kim KM Kim SW Cho NH Trabecular bone score as an indicator for skeletal deterioration in diabetes J Clin Endocrinol Metab 2015 100 475 482 10.1210/jc.2014-2047 25368976
12. Ho-Pham LT Tran B Do AT Nguyen TV Association between pre-diabetes, type 2 diabetes and trabecular bone score: the Vietnam osteoporosis study Diabetes Res Clin Pract 2019 155 107790 10.1016/j.diabres.2019.107790 31325536
13. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999 to 2010. Vital and health statistics Ser 1, programs and collection procedures. 2013. p. 1 to 37. 25078429
14. Yan G Huang Y Cao H Wu J Jiang N Cao X Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study BMC Womens Health 2019 19 110 10.1186/s12905-019-0808-0 31409345 PMC6692954
15. Goldshtein I Nguyen AM dePapp AE Ish-Shalom S Chandler JM Chodick G Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients Arch Osteoporos 2018 13 15 10.1007/s11657-018-0432-x 29502187
16. Wang L Li T Liu J Wu X Wang H Li X Association between glycosylated hemoglobin A1c and bone biochemical markers in type 2 diabetic postmenopausal women: a cross-sectional study BMC Endocr Disord 2019 19 31 10.1186/s12902-019-0357-4 30866902 PMC6416956
17. Karimifar M Pasha MA Salari A Zamani A Salesi M Motaghi P Evaluation of bone loss in diabetic postmenopausal women J Res Med Sci 2012 17 1033 1038 23833577 PMC3702084
18. Takagi M Kasayama S Yamamoto T Motomura T Hashimoto K Yamamoto H Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells J Bone Mineral Res 1997 12 439 446 10.1359/jbmr.1997.12.3.439 9076587
19. Viguet-Carrin S Roux JP Arlot ME Merabet Z Leeming DJ Byrjalsen I Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae Bone 2006 39 1073 1079 10.1016/j.bone.2006.05.013 16829221
20. Ding KH Wang ZZ Hamrick MW Deng ZB Zhou L Kang B Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss Biochem Biophys Res Commun 2006 340 1091 1097 10.1016/j.bbrc.2005.12.107 16403440
21. Sroga GE Wu PC Vashishth D Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone PLoS ONE 2015 10 e0117046 10.1371/journal.pone.0117046 25629402 PMC4309541
22. Terada M Inaba M Yano Y Hasuma T Nishizawa Y Morii H Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells Bone 1998 22 17 23 10.1016/S8756-3282(97)00220-2 9437509
23. McCarthy AD Etcheverry SB Cortizo AM Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development Acta Diabetol 2001 38 113 122 10.1007/s005920170007 11827431
24. Morabito N Russo GT Gaudio A Lasco A Catalano A Morini E The lively cytokines network in beta-thalassemia major-related osteoporosis Bone 2007 40 1588 1594 10.1016/j.bone.2007.02.020 17412659
25. Russo GT Giandalia A Romeo EL Nunziata M Muscianisi M Ruffo MC Fracture risk in type 2 diabetes: current perspectives and gender differences Int J Endocrinol. 2016 2016 1615735 10.1155/2016/1615735 28044077 PMC5164892
26. Ma J Han L Zhou X Li Z Clinical significance of vitamin-D and other bone turnover markers on bone mineral density in patients with gestational diabetes mellitus Pak J Med Sci 2022 38 23 27 35035395 10.12669/pjms.38.1.4461 PMC8713226
27. Yang S Shen X Association and relative importance of multiple obesity measures with bone mineral density: the National Health and Nutrition Examination Survey 2005 to 2006 Arch Osteoporos 2015 10 14 10.1007/s11657-015-0219-2 25957066
28. Méndez JP Rojano-Mejía D Pedraza J Coral-Vázquez RM Soriano R García-García E Bone mineral density in postmenopausal Mexican-mestizo women with normal body mass index, overweight or obesity Menopause 2013 20 568 572 10.1097/gme.0b013e318277694f 23615649
29. Riis BJ Rødbro P Christiansen C The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis Calcif Tissue Int 1986 38 318 322 10.1007/BF02555743 3089552
30. Walsh JS Henriksen DB Feeding and bone Arch Biochem Biophys 2010 503 11 19 10.1016/j.abb.2010.06.020 20599659
Publication and source details

Original title: Association of a history of gestational diabetes mellitus with osteoporosis, bone mineral density, and trabecular bone score in postmenopausal women

Boqi Lu; Liping Zhang

Diabetology & Metabolic Syndrome · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T15:20:37.017019+00:00

DOI: 10.1186/s13098-023-01194-8 · PMC10605046